Traducción y análisis de palabras por inteligencia artificial
En esta página puede obtener un análisis detallado de una palabra o frase, producido utilizando la mejor tecnología de inteligencia artificial hasta la fecha:
- cómo se usa la palabra
- frecuencia de uso
- se utiliza con más frecuencia en el habla oral o escrita
- opciones de traducción
- ejemplos de uso (varias frases con traducción)
- etimología
Qué (quién) es was withdrawn from circulation - definición
![[[3D rendering]] of a [[high resolution computed tomography]] of the [[thorax]]. The anterior thoracic wall, the airways and the pulmonary vessels anterior to the [[root of the lung]] have been digitally removed in order to visualize the different levels of the pulmonary circulation.](https://commons.wikimedia.org/wiki/Special:FilePath/3D CT of thorax, annotated.jpg?width=200 "[[3D rendering]] of a [[high resolution computed tomography]] of the [[thorax]]. The anterior thoracic wall, the airways and the pulmonary vessels anterior to the [[root of the lung]] have been digitally removed in order to visualize the different levels of the pulmonary circulation.")
![Image showing main pulmonary artery coursing ventrally to the [[aortic root]] and [[trachea]]. The right pulmonary artery passes dorsally to the [[ascending aorta]], while the left pulmonary artery passes ventrally to the [[descending aorta]].](https://commons.wikimedia.org/wiki/Special:FilePath/Relations of the aorta, trachea, esophagus and other heart structures.png?width=200 "Image showing main pulmonary artery coursing ventrally to the [[aortic root]] and [[trachea]]. The right pulmonary artery passes dorsally to the [[ascending aorta]], while the left pulmonary artery passes ventrally to the [[descending aorta]].")
Wikipedia
Drugs or medicines may be withdrawn from commercial markets because of risks to patients, but also because of commercial reasons (e.g. lack of demand and relatively high production costs). Where risks or harms is the reason for withdrawal, this will usually have been prompted by unexpected adverse effects that were not detected during Phase III clinical trials, i.e. they were only made apparent from postmarketing surveillance data collected from the wider community over longer periods of time.
This list is not limited to drugs that were ever approved by the FDA. Some of them (lumiracoxib, rimonabant, tolrestat, ximelagatran and ximelidine, for example) were approved to be marketed in Europe but had not yet been approved for marketing in the US, when side effects became clear and their developers pulled them from the market. Some drugs in this list (e.g. LSD) were never approved for marketing in the US or Europe.
